4179 |
iFR-SWEDEHEART: Five-year Outcomes of a Randomized Trial of iFR-guided vs. FFR-guided PCI |
Matthias Gotberg |
Apr. 08. 22 |
4178 |
Clinical Impact of Patient-Prosthesis Mismatch After TAVR |
Duk-Woo Park |
Apr. 08. 22 |
4177 |
Optimal Management for Failure TAVR Valve |
Vinayak Bapat |
Apr. 08. 22 |
4176 |
Optimal TAVR Procedure for Bicuspid AV: Self Expandable Device |
Eberhard Grube |
Apr. 08. 22 |
4175 |
Pragmatic Antithrombotic Strategies According to Bleeding and Ischemic Risk |
Duk-Woo Park |
Apr. 08. 22 |
4174 |
Escalation Antithrombotic Strategy: When and How? |
Davide Capodanno |
Apr. 08. 22 |
4173 |
Ischemic and Bleeding Risk Prediction After ACS and PCI |
Sunil Rao |
Apr. 08. 22 |
4172 |
Optimal DAPT Duration for PCI Patients at High Beeding Risk |
Roxana Mehran |
Apr. 08. 22 |
4171 |
Best Stent and Best Antithrombotic Strategy in High Bleeding Risk Patients: MASTER-DAPT, ONYX-ONE, LEADER-FREE and Others |
Marco Valgimigli |
Apr. 08. 22 |
4170 |
Imaging Based Coronary Physiology in the Clinical Practice: CTFFR and AngioFFR |
Bon-Kwon Koo |
Apr. 08. 22 |